TR199802108T2 - Ibandronat içeren oral farmasötik bir formülasyon. - Google Patents

Ibandronat içeren oral farmasötik bir formülasyon.

Info

Publication number
TR199802108T2
TR199802108T2 TR1998/02108T TR9802108T TR199802108T2 TR 199802108 T2 TR199802108 T2 TR 199802108T2 TR 1998/02108 T TR1998/02108 T TR 1998/02108T TR 9802108 T TR9802108 T TR 9802108T TR 199802108 T2 TR199802108 T2 TR 199802108T2
Authority
TR
Turkey
Prior art keywords
active ingredient
pharmaceutical formulation
formulation containing
oral pharmaceutical
ibandronate
Prior art date
Application number
TR1998/02108T
Other languages
English (en)
Inventor
Mockel Jorn
Gabel Rolf-Dieter
Woog Heinrich
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199802108(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of TR199802108T2 publication Critical patent/TR199802108T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bulus, oral uygulama için aktif terkip maddesi formunda ibandronat veya bunun fizyolojik olarak tolere edilebilir bir tuzunu içeren ve iyi tolere edilen farmasötik bilesimlere iliskindir. Uygulama formu, aktif terkip maddesini içeren ve aktif terkip maddesinin hizli bir sekilde salinmasini saglayacak bir tarzda aktif terkip maddesi içermeyen bir kaplama ile çevrelenen bir iç kisimdan olusur.
TR1998/02108T 1996-04-20 1997-04-21 Ibandronat içeren oral farmasötik bir formülasyon. TR199802108T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation

Publications (1)

Publication Number Publication Date
TR199802108T2 true TR199802108T2 (tr) 1999-01-18

Family

ID=7791961

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02108T TR199802108T2 (tr) 1996-04-20 1997-04-21 Ibandronat içeren oral farmasötik bir formülasyon.

Country Status (26)

Country Link
US (2) US6143326A (tr)
EP (2) EP0936913B2 (tr)
JP (2) JP5037746B2 (tr)
CN (1) CN101152160A (tr)
AR (2) AR006652A1 (tr)
AT (1) ATE404207T1 (tr)
AU (1) AU722516B2 (tr)
BR (1) BR9708785A (tr)
CA (1) CA2251886C (tr)
CO (1) CO4820394A1 (tr)
CZ (1) CZ297341B6 (tr)
DE (2) DE19615812A1 (tr)
DK (1) DK0936913T4 (tr)
ES (1) ES2313735T5 (tr)
HU (1) HU228389B1 (tr)
IL (2) IL126655A (tr)
NO (1) NO319162B1 (tr)
NZ (1) NZ332314A (tr)
PA (1) PA8427301A1 (tr)
PL (2) PL191363B1 (tr)
PT (1) PT936913E (tr)
RU (1) RU2193881C2 (tr)
SI (1) SI0936913T2 (tr)
TR (1) TR199802108T2 (tr)
WO (1) WO1997039755A1 (tr)
ZA (1) ZA973331B (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
SK9132003A3 (en) * 2001-12-19 2004-02-03 Astrazeneca Ab A film coating composition, a coating film, pharmaceutical formulation comprising same and a process for its production
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
PT1476138E (pt) 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
WO2008013084A1 (fr) * 2006-07-25 2008-01-31 Kowa Company, Ltd. Préparation enrobée de sucre et son procédé de fabrication
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) * 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
CA2803052C (en) * 2010-08-31 2014-10-28 Toray Industries, Inc. Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
JP5832645B2 (ja) * 2011-06-17 2015-12-16 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ 医薬剤形又は栄養補助剤形に適したコーティング組成物
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (tr) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
BR9307859A (pt) * 1993-05-15 1996-01-09 Boehringer Mannheim Gmbh Comprimido com biodisponibilidade aperfeiçoada que contérn ácido
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
SI0936913T2 (sl) 2012-11-30
CA2251886C (en) 2008-06-17
PL191910B1 (pl) 2006-07-31
US6143326A (en) 2000-11-07
DE19615812A1 (de) 1997-10-23
JP2008285500A (ja) 2008-11-27
PA8427301A1 (es) 2002-07-30
NO319162B1 (no) 2005-06-27
NO984881L (no) 1998-10-19
EP0936913B1 (de) 2008-08-13
DK0936913T3 (da) 2008-10-20
IL126655A0 (en) 1999-08-17
EP1658852A1 (de) 2006-05-24
ES2313735T3 (es) 2009-03-01
JP2000508673A (ja) 2000-07-11
HUP9903407A2 (hu) 2000-04-28
AR006652A1 (es) 1999-09-08
US20050089573A1 (en) 2005-04-28
ZA973331B (en) 1998-10-19
CN101152160A (zh) 2008-04-02
PL191363B1 (pl) 2006-05-31
DK0936913T4 (da) 2012-11-19
JP5557989B2 (ja) 2014-07-23
IL126655A (en) 2004-12-15
NO984881D0 (no) 1998-10-19
AU722516B2 (en) 2000-08-03
AU2638297A (en) 1997-11-12
BR9708785A (pt) 1999-08-03
RU2193881C2 (ru) 2002-12-10
PL329347A1 (en) 1999-03-29
IL163930A0 (en) 2005-12-18
CA2251886A1 (en) 1997-10-30
CZ336498A3 (cs) 2000-01-12
ES2313735T5 (es) 2012-12-07
PT936913E (pt) 2008-09-25
JP5037746B2 (ja) 2012-10-03
EP0936913B2 (de) 2012-09-19
DE59712959D1 (de) 2008-09-25
HU228389B1 (en) 2013-03-28
HUP9903407A3 (en) 2000-11-28
WO1997039755A1 (de) 1997-10-30
EP1658852B1 (de) 2016-11-09
CZ297341B6 (cs) 2006-11-15
AR054350A2 (es) 2007-06-20
EP0936913A1 (de) 1999-08-25
SI0936913T1 (sl) 2008-12-31
ATE404207T1 (de) 2008-08-15
CO4820394A1 (es) 1999-07-28
NZ332314A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
FI973828L (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
RU93004469A (ru) Формы дозирования, обеспечивающие продленное выделение активного ингредиента
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
DE69902875D1 (de) Tts enthaltend ein antioxidans
DK0479005T3 (da) Farmaceutisk præparat i form af en gel i dispenseremballage
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
MXPA03001762A (es) Proceso para preparar composiciones farmaceuticas para uso con formulaciones de gelatina suave.
TR199900336T2 (tr) EAA antagonistleri olarak tetrahidrokinolin türevleri.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
UA40636C2 (uk) Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
DE69827466D1 (de) Geschmacksneutrale pharmazeutische zusammensetzungen
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization